1858 Wealth Management LLC Makes New $224,000 Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

1858 Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 314 shares of the biopharmaceutical company’s stock, valued at approximately $224,000.

Other large investors have also recently modified their holdings of the company. State Street Corp raised its position in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after purchasing an additional 61,277 shares in the last quarter. International Assets Investment Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after buying an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after buying an additional 11,499 shares during the period. Swiss National Bank raised its holdings in shares of Regeneron Pharmaceuticals by 0.6% in the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in Regeneron Pharmaceuticals by 1.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 301,508 shares of the biopharmaceutical company’s stock worth $316,957,000 after acquiring an additional 3,866 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

REGN has been the subject of several recent research reports. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Oppenheimer cut their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. Leerink Partners dropped their price objective on Regeneron Pharmaceuticals from $980.00 to $862.00 and set a “market perform” rating on the stock in a research report on Tuesday. Finally, Wells Fargo & Company decreased their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research report on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $983.65.

Regeneron Pharmaceuticals Trading Up 4.5 %

Shares of NASDAQ:REGN opened at $697.05 on Wednesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The stock has a market cap of $76.60 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.60 and a beta of 0.08. The business has a 50-day moving average price of $719.16 and a 200-day moving average price of $918.90.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The company had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the firm posted $11.86 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.50%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.